Biochemical response to ursodeoxycholic acid predicts long-term outcome in Japanese patients with primary biliary cirrhosis

Hepatology Research

Volumn 41, Issue 4, 2011, Pages 310-317

  Azemoto, Nobuaki ^a   Kumagi, Teru ^a   Abe, Masanori ^a   Konishi, Ichiro ^a   Matsuura, Bunzo ^a   Hiasa, Yoichi ^a   Onji, Morikazu ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Biochemical response; Primary biliary cirrhosis; Ursodeoxycholic acid

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ANTINUCLEAR ANTIBODY; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MITOCHONDRION ANTIBODY; URSODEOXYCHOLIC ACID;

ADULT; ADVANCED CANCER; AGE; AGED; ARTICLE; BILIARY CIRRHOSIS; CANCER STAGING; CONTROLLED STUDY; FEMALE; HUMAN; JAPANESE; MALE; MEDICAL RECORD REVIEW; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTHROMBIN TIME; RETROSPECTIVE STUDY; SEX DIFFERENCE; SURVIVAL RATE; THROMBOCYTE; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 79952853530     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2011.00782.x     Document Type: Article

References (22)

1. Kumagi T, Heathcote EJ. Primary biliary cirrhosis. Orphanet J Rare Dis 2008; 3: 1.
2. Abe M, Onji M. Natural history of primary biliary cirrhosis. Hepatol Res 2008; 38: 639-45.
3. Kumagi T, Onji M. Presentation and diagnosis of primary biliary cirrhosis in the 21st Century. Clin Liver Dis 2008; 12: 243-59.
4. Mahl TC, Shockcor W, Boyer JL. Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24years. J Hepatol 1994; 20: 707-13.
5. Springer J, Cauch-Dudek K, O'Rourke K, Wanless IR, Heathcote EJ. Asymptomatic primary biliary cirrhosis: a study of its natural history and prognosis. Am J Gastroenterol 1999; 94: 47-53.
6. Nakamura M, Takii Y, Mori T etal. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 2007; 45: 118-27.
7. Poupon RE, Balkau B, Eschwe'ge E, Poupon R, UDCA-PBC Study Group. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med 1991; 324: 1548-54.
8. Heathcote EJ, Cauch-Dudek K, Walker V etal. The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994; 19: 1149-56.
9. Combes B, Carithers RL Jr, Maddrey WC etal. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995; 22: 759-66.
10. Angulo P, Batts KP, Therneau TM, Jorgensen RA, Dickson ER, Lindor KD. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. Hepatology 1999; 29: 644-7.
11. Poupon RE, Lindor KD, Parés A, Chazouilleres O, Poupon R, Heathcote EJ. Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol 2003; 39: 12-16.
12. Corpechot C, Carrat F, Bonnand AM, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 2000; 32: 1196-9.
13. van Hoogstraten HJ, Hansen BE, van Buuren HR, ten Kate FJ, van Berge-Henegouwen GP, Schalm SW. Prognostic factors and long-term effects of ursodeoxycholic acid on liver biochemical parameters in patients with primary biliary cirrhosis. Dutch Multi-Centre PBC Study Group. J Hepatol 1999; 31: 256-62.
14. ter Borg PC, Schalm SW, Hansen BE, van Buuren HR, Dutch PBC Study Group. Prognosis of ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Results of a 10-year cohort study involving 297 patients. Am J Gastroenterol 2006; 101: 2044-50.
15. Corpechot C, Carrat F, Bahr A, Chre'tien Y, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 2005; 128: 297-303.
16. Kumagi T, Guindi M, Fischer SE etal. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol 2010; 105: 2186-94.
17. Corpechot C, Abenavoli L, Rabahi N etal. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 2008; 48: 871-7.
18. Parés A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 2006; 130: 715-20.
19. Kuiper E, Hansen B, De Vries R, Den Ouden-Muller J, Van Ditzhuijsen T, Haagsma E. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology 2009; 136: 1281-7.
20. Azemoto N, Abe M, Murata Y etal. Early biochemical response to ursodeoxycholic acid predicts symptom development with asymptomatic primary biliary cirrhosis. J Gastroenterol 2009; 44: 630-4.
21. Scheuer P. Primary biliary cirrhosis. Proc R Soc Med 1967; 60: 1257-60.
22. Angulo P, Lindor KD, Therneau TM etal. Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. Liver 1999; 19: 115-21.